• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
NMS-1286937

NMS-1286937

Product ID N5072
Cas No. 1034616-18-6
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $142.80 In stock
5 mg $228.10 In stock
10 mg $346.10 Please Inquire
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

NMS-1286937 is an inhibitor of polo-like kinase 1 (PLK1) that is currently in clinical trials as a potential treatment for various cancers; it exhibits anticancer chemotherapeutic activity. In osteosarcoma cells, NMS-1286937 induces cell cycle arrest and apoptosis and inhibits cell growth. In animal models of acute myelogenous leukemia (AML), this compound increases survival time and decreases tumor cell infiltration. Additionally, NMS-1286937 inhibits cell proliferation and induces apoptosis, cell cycle arrest, and tumor regression in cellular and animal models of colon cancer.

Product Info

Cas No.

1034616-18-6

Purity

≥98%

Formula

C24H27F3N8O3

Formula Wt.

532.52

IUPAC Name

1-(2-Hydroxyethyl)-8-{[5-(4-methyl-1-piperazinyl)-2-(trifluoromethoxy)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide

Synonym

NMS1286937, NMS-P937

Solubility

DMSO 42 mg/mL warmed (78.87 mM) Ethanol 10 mg/mL warmed (18.77 mM) Water Insoluble

Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

N5072 MSDS PDF

Info Sheet

N5072 Info Sheet PDF

References

Sero V, Tavanti E, Vella S, et al. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Invest New Drugs. 2014 Dec;32(6):1167-80. PMID: 25193492.

Casolaro A, Golay J, Albanese C, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8(3):e58424. PMID: 23520509.

Valsasina B, Beria I, Alli C, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr;11(4):1006-16. PMID: 22319201.

Beria I, Bossi RT, Brasca MG, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74. PMID: 21470862.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • P0256

    Pantoprazole Sodium Sesquihydrate

    H+/K+ ATPase and ROCK-2 inhibitor.

    ≥98%
  • S0501

    SB-939

    HDAC inhibitor.

    ≥98%
  • T1844

    Telbivudine

    Nucleoside (thymidine) analog; DNA chain termin...

    ≥98%
  • T0115

    Taxol Side Chain Acid

    Side chain commonly attached to taxanes.

    ≥98%
  • C0275

    Castanospermine

    O-GlcNAcase inhibitor.

    ≥98%
  • P3348

    Pimecrolimus

    Calcineurin inhibitor, potential TRPV1 agonist....

    ≥99%
  • D3212

    2′,3′-Dideoxycytidine

    Pyrimidine nucleoside (cytidine) analog; DNA ch...

    ≥98%
  • P8168

    Puromycin Dihydrochloride

    Protein synthesis inhibitor, DPP2 and metallope...

    ≥98%
  • N9874

    Nystatin

    Polyene macrolide, induces pore formation in fu...

    4400u/mg
  • C0173

    Carmustine

    Nitrosourea, DNA alkylator.

    ≥98%
  • J0379

    Jatrorrhizine Chloride

    Alkaloid compound originally found in Corydalis...

    ≥95%
  • G5320

    GNF-2

    Abl inhibitor.

    ≥98%
  • A2046

    Aflatoxin B2

    Mycotoxin produced by species of Aspergillus; D...

    ≥98%
  • R2810

    Recombinant Multi-epitope Chimeric HIV Antigen 1

    Recombinant HIV-1 multi-epitope chimeric antige...

    ≥95%
  • A8644

    AVL-292

    BTK inhibitor.

    ≥98%
  • F1607

    Febuxostat

    Xanthine oxidase inhibitor.

    ≥98%
  • A1017

    Aceclofenac

    Diclofenac analog, NSAID; COX-2 inhibitor.

    ≥98%
  • C3477

    Citalopram Hydrobromide

    SERT inhibitor.

    ≥98%
  • D1850

    Demethoxycurcumin

    Curcumin derivative; AMPK activator, STAT3 and ...

    ≥98%
  • S7601

    Statil

    Aldose reductase inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only